Key Points
- Harlan Robins sold 10,000 shares of Adaptive Biotechnologies on March 2 at an average price of $15.72 for $157,200, reducing his holding by 0.85% to 1,169,524 shares (about $18.38M).
- Recent quarter beat expectations: ADPT reported EPS of ($0.09) versus consensus ($0.19) and revenue of $71.68M (up 51% year-over-year) versus $59.38M expected.
- Shares traded around $16.12 with a $2.48B market cap; analysts give an average rating of "Moderate Buy" with an average price target of $18.25 (seven Buys, one Hold, one Sell).
Adaptive Biotechnologies Corporation (NASDAQ:ADPT - Get Free Report) insider Harlan Robins sold 10,000 shares of the business's stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $15.72, for a total transaction of $157,200.00. Following the completion of the sale, the insider owned 1,169,524 shares in the company, valued at approximately $18,384,917.28. The trade was a 0.85% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Adaptive Biotechnologies Price Performance
Shares of Adaptive Biotechnologies stock traded down $0.32 during trading on Thursday, reaching $16.12. 212,915 shares of the stock traded hands, compared to its average volume of 1,844,309. The company has a market capitalization of $2.48 billion, a price-to-earnings ratio of -40.30 and a beta of 2.19. The business has a fifty day simple moving average of $16.85 and a two-hundred day simple moving average of $15.79. Adaptive Biotechnologies Corporation has a 52-week low of $6.26 and a 52-week high of $20.76.
Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last issued its quarterly earnings data on Thursday, February 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.10. Adaptive Biotechnologies had a negative return on equity of 46.68% and a negative net margin of 21.48%.The business had revenue of $71.68 million for the quarter, compared to analysts' expectations of $59.38 million. During the same period in the prior year, the firm earned ($0.23) EPS. The company's revenue for the quarter was up 51.0% on a year-over-year basis. On average, research analysts predict that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Several analysts recently weighed in on ADPT shares. TD Cowen restated a "buy" rating on shares of Adaptive Biotechnologies in a report on Friday, February 6th. Wall Street Zen raised shares of Adaptive Biotechnologies from a "hold" rating to a "buy" rating in a research note on Sunday, February 8th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Adaptive Biotechnologies in a report on Wednesday, January 21st. Morgan Stanley assumed coverage on shares of Adaptive Biotechnologies in a research note on Monday, December 1st. They issued an "equal weight" rating and a $21.00 price objective for the company. Finally, JPMorgan Chase & Co. upped their target price on Adaptive Biotechnologies from $20.00 to $21.00 and gave the company an "overweight" rating in a research note on Friday, February 6th. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Adaptive Biotechnologies has an average rating of "Moderate Buy" and an average price target of $18.25.
Check Out Our Latest Stock Report on ADPT
Institutional Trading of Adaptive Biotechnologies
Institutional investors and hedge funds have recently modified their holdings of the stock. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Adaptive Biotechnologies in the fourth quarter valued at approximately $28,000. Sound Income Strategies LLC bought a new stake in Adaptive Biotechnologies during the 3rd quarter valued at $30,000. EverSource Wealth Advisors LLC lifted its holdings in shares of Adaptive Biotechnologies by 197.1% in the 4th quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company's stock worth $38,000 after buying an additional 1,565 shares during the period. Assetmark Inc. grew its position in shares of Adaptive Biotechnologies by 867.9% during the 4th quarter. Assetmark Inc. now owns 3,020 shares of the company's stock worth $49,000 after buying an additional 2,708 shares in the last quarter. Finally, T. Rowe Price Investment Management Inc. purchased a new position in shares of Adaptive Biotechnologies during the fourth quarter valued at $51,000. Institutional investors own 99.17% of the company's stock.
About Adaptive Biotechnologies
(
Get Free Report)
Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.
The company's flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
